Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2023; 15(1): 186-194
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.186
Local recurrence after successful endoscopic submucosal dissection for rectal mucinous mucosal adenocarcinoma: A case report
Yuki Murakami, Hiroki Tanabe, Yusuke Ono, Yuya Sugiyama, Yu Kobayashi, Takehito Kunogi, Takahiro Sasaki, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Sayaka Yuzawa, Kentaro Moriichi, Yusuke Mizukami, Mikihiro Fujiya, Toshikatsu Okumura
Yuki Murakami, Hiroki Tanabe, Yuya Sugiyama, Yu Kobayashi, Takehito Kunogi, Takahiro Sasaki, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Yusuke Mizukami, Mikihiro Fujiya, Toshikatsu Okumura, Division of Metabolism and Biosystemic Science, Department of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Hokkaido, Japan
Yusuke Ono, Yusuke Mizukami, Institute of Biomedical Research, Sapporo-Higashi Tokushukai Hospita, Sapporo 065-0033, Hokkaido, Japan
Sayaka Yuzawa, Department of Diagnostic Pathology, Asahikawa Medical University, Asahikawa 078-8510, Hokkaido, Japan
Author contributions: Murakami Y designed this case report and performed the whole study; Tanabe H helped to write the manuscript. Ono Y and Mizukami Y performed the genetic analyses. Sugiyama Y, Kobayashi Y, Takahashi K, Sasaki T, and Takahashi K were involved in the patient’s diagnosis and endoscopic treatment. Ando K and Ueno N organized the patient’s treatment in the hospital. Moriichi K and Kashima S processed the experimental data and performed the analysis. Yuzawa S performed the histological analysis. Fujiya M and Okumura T supervised the research.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this case report.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hiroki Tanabe, MD, PhD, Associate Professor, Division of Metabolism and Biosystemic Science, Department of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa 078-8510, Hokkaido, Japan. tant@asahikawa-med.ac.jp
Received: October 8, 2022
Peer-review started: October 8, 2022
First decision: October 17, 2022
Revised: October 31, 2022
Accepted: December 6, 2022
Article in press: December 6, 2022
Published online: January 15, 2023
Core Tip

Core Tip: Colorectal mucinous adenocarcinoma, as characterized by an abundant mucinous component, is a rare histological subtype frequently diagnosed at an advanced stage. Intramucosal mucinous adenocarcinoma was dissected by endoscopic submucosal dissection and local recurrence was detected three years after the treatment. Genetic analysis showed pathogenic alterations of RNF43, TP53, and SMAD4. This case of mucinous mucosal adenocarcinoma was suggested to have an aggressive phenotype based on the treatment course and advanced genotype identified by target sequencing. Careful and close follow-up should be performed, and additional surgery should be considered when managing patients with mucinous adenocarcinoma.